Cell & Gene Therapy Manufacturing Services Market Size to Grow by USD 38.9 billion from 2024-2031 | Merck, Thermo Fisher Scientific, Catalent, Lonza, Takara Bio

The global Cell & Gene Therapy Manufacturing Services Market is poised for remarkable growth, as indicated by SNS Insider’s report. The market, valued at USD 6.1 billion in 2023, is forecasted to surge to USD 38.9 billion by 2031, reflecting an impressive compound annual growth rate (CAGR) of 22.3% during the forecast period from 2024 to 2031.

The accelerating demand for cell and gene therapies, fueled by the escalating prevalence of chronic diseases and genetic disorders, coupled with advancements in biotechnology, is a primary driver propelling this exponential growth. Cell and gene therapies offer promising treatment options for a wide array of conditions, ranging from cancer to genetic disorders, and have demonstrated remarkable efficacy in several clinical trials.

The increasing investment in research and development activities, along with the rising number of collaborations and partnerships between pharmaceutical companies and contract manufacturing organizations (CMOs), are further contributing to the expansion of the cell and gene therapy manufacturing services market. Moreover, supportive regulatory frameworks and initiatives aimed at streamlining the manufacturing process and accelerating the commercialization of advanced therapies are bolstering market growth.

Get Free Sample Report of Cell & Gene Therapy Manufacturing Services Market @ https://www.snsinsider.com/sample-request/1187

Key Takeaways from the Cell & Gene Therapy Manufacturing Services Market Study:

• Robust Pipeline of Cell & Gene Therapies Fueling Demand: With over 1,000 cell and gene therapy products in development globally, the need for specialized manufacturing services is skyrocketing as companies race to commercialize these cutting-edge treatments.
• Contract Manufacturing Dominates: Due to the complexity and cost of building in-house manufacturing capabilities, an estimated 70% of cell and gene therapy developers are outsourcing production to contract manufacturing organizations (CMOs).
• Strong Growth Across All Regions: While North America currently accounts for the largest market share, Asia Pacific is poised to experience the highest CAGR from 2024 to 2031 as major biopharma hubs emerge in countries like China, Japan, and South Korea.

Regional Analysis:

• North America: Capturing over 40% of the market in 2023, driven by the U.S. biotech industry and early adoption of cell and gene therapies.
• Europe: The second-largest market, benefiting from streamlined regulation and government initiatives spurring growth.
• Asia Pacific: Anticipated to witness the fastest growth, fueled by increasing R&D activity and the establishment of manufacturing facilities by global pharmaceutical companies.

Key Developments:

• Major investments by CMOs to expand capacity and capabilities, such as Thermo Fisher’s new $180 million facility and Resilience’s $1.2 billion manufacturing site.
• Strategic partnerships between therapy developers and CMOs, exemplified by Bristol Myers Squibb’s $900 million deal with Catalent.
• Entry of new players like Samsung Biologics and Wuxi AppTec into the cell and gene therapy CDMO space.
• Intense competition among established CMOs like Lonza, Catalent, Fujifilm, Merck, and Thermo Fisher to secure manufacturing contracts.

Ask Your Query Before Buying this Research Report @ https://www.snsinsider.com/enquiry/1187

List of Cell & Gene Therapy Manufacturing Services Companies Profiled in Report:

• Merck KGaA
• Thermo Fisher Scientific
• Catalent Inc.
• Lonza
• Takara Bio Inc.
• Wuxi Advanced Therapies
• Hoffmann-La Roche Ltd
• Samsung Biologics
• Bluebird Bio Inc.
• Novartis AG
• Boehringer Ingelheim
• Hitachi Chemical Co. Ltd.
• Miltenyi Biotec
• Cellular Therapeutic

Cell & Gene Therapy Manufacturing Services Industry Segmentation as Follows:

By Type

• Cell Therapy
  • Allogeneic
    • Mesenchymal Stem Cells
    • T-cells
    • Induced Pluripotent Stem Cells
    • Natural Killer Cells
    • Hematopoietic Stem Cells
    • Other Allogeneic Cells
  • Autologous
    • T-cells
    • Hematopoietic Stem Cells
    • Mesenchymal Stem Cells
    • Natural Killer Cells
    • Other Autologous Cells
  • Viral Vector
    • Retroviral Vectors
    • Adeno-associated Virus Vectors
    • Other Viral Vectors
• Gene Therapy
  • Viral Vector
    • Retroviral Vectors
    • Adeno-associated Virus Vectors
    • Other Viral Vectors
  • Non-viral Vector
    • Oligonucleotides
    • Other Non-viral Vectors

By Indication

• Oncology Diseases
• Cardiovascular Diseases
• Orthopedic Diseases
• Ophthalmology Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Other Indications

By Application

• Clinical Manufacturing
• Commercial Manufacturing

Buy Cell & Gene Therapy Manufacturing Services Market report @ https://www.snsinsider.com/checkout/1187

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

Email,

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

Website: https://www.snsinsider.com/